Sofiva Genomics Co.,Ltd. (TPEX:6615)

Market Cap	735.26M -14.7%
Revenue (ttm)	393.48M -15.3%
Net Income	-10.18M
EPS	-0.47
Shares Out	21.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.30 (0.88%)
Ex-Dividend Date	Jun 27, 2025

Volume	78,107
Average Volume	76,968
Open	34.35
Previous Close	34.35
Day's Range	34.05 - 34.40
52-Week Range	28.90 - 41.45
Beta	0.17
RSI	65.98
Earnings Date	Mar 18, 2026

About Sofiva Genomics

Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessm...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2012
• Employees: 104
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6615

Financial Performance

In 2024, Sofiva Genomics's revenue was 453.31 million, a decrease of -2.89% compared to the previous year's 466.80 million. Earnings were 18.43 million, an increase of 59.89%.